Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. (Q53153505)

From Wikidata

Jump to navigation Jump to search

scientific article published in February 2013

Language	Label	Description	Also known as
English	Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer.	scientific article published in February 2013

Statements

scholarly article

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22766692

Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. (English)

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22766692

chemoradiotherapy

0 references

author name string

Masayuki Sho

1

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22766692

Takahiro Akahori

2

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22766692

Toshihiro Tanaka

3

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22766692

Shoichi Kinoshita

4

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22766692

Tetsuro Tamamoto

5

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22766692

Takeo Nomi

6

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22766692

Ichiro Yamato

7

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22766692

Daisuke Hokuto

8

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22766692

Satoshi Yasuda

9

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22766692

Chihiro Kawaguchi

10

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22766692

Hideyuki Nishiofuku

11

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22766692

Nagaaki Marugami

12

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22766692

Yasunori Enomonoto

13

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22766692

Takahiko Kasai

14

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22766692

Masatoshi Hasegawa

15

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22766692

Kimihiko Kichikawa

16

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22766692

Yoshiyuki Nakajima

17

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22766692

publication date

1 February 2013

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22766692

Journal of Hepato-biliary-Pancreatic Sciences

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22766692

20

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22766692

2

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22766692

197-205

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22766692

https://scigraph.springernature.com/pub.10.1007/s00534-012-0532-8

0 references

Pancreatic cancer: surgery alone is not sufficient

1 reference

https://api.crossref.org/works/10.1007%2FS00534-012-0532-8

21 January 2018

Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?

1 reference

https://api.crossref.org/works/10.1007%2FS00534-012-0532-8

21 January 2018

Pancreatic adenocarcinoma: the actual 5-year survivors

1 reference

https://api.crossref.org/works/10.1007%2FS00534-012-0532-8

21 January 2018

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00534-012-0532-8

21 January 2018

A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00534-012-0532-8

21 January 2018

Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00534-012-0532-8

21 January 2018

Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival

1 reference

https://api.crossref.org/works/10.1007%2FS00534-012-0532-8

21 January 2018

A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database

1 reference

https://api.crossref.org/works/10.1007%2FS00534-012-0532-8

21 January 2018

Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00534-012-0532-8

21 January 2018

Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00534-012-0532-8

21 January 2018

Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00534-012-0532-8

21 January 2018

Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial

1 reference

https://api.crossref.org/works/10.1007%2FS00534-012-0532-8

21 January 2018

Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head

1 reference

https://api.crossref.org/works/10.1007%2FS00534-012-0532-8

21 January 2018

Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).

1 reference

https://api.crossref.org/works/10.1007%2FS00534-012-0532-8

21 January 2018

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages

1 reference

https://api.crossref.org/works/10.1007%2FS00534-012-0532-8

21 January 2018

Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head

1 reference

https://api.crossref.org/works/10.1007%2FS00534-012-0532-8

21 January 2018

Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy

1 reference

https://api.crossref.org/works/10.1007%2FS00534-012-0532-8

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS00534-012-0532-8

21 January 2018

Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition.

1 reference

https://api.crossref.org/works/10.1007%2FS00534-012-0532-8

21 January 2018

Postoperative pancreatic fistula: an international study group (ISGPF) definition.

1 reference

https://api.crossref.org/works/10.1007%2FS00534-012-0532-8

21 January 2018

Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00534-012-0532-8

21 January 2018

A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00534-012-0532-8

21 January 2018

Preoperative chemoradiation reduces the risk of pancreatic fistula after distal pancreatectomy for pancreatic adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00534-012-0532-8

21 January 2018

Management of delayed major visceral arterial bleeding after pancreatic surgery

1 reference

https://api.crossref.org/works/10.1007%2FS00534-012-0532-8

21 January 2018

Pseudoaneurysm of the lingual artery after concurrent intra-arterial chemotherapy with radiotherapy for advanced tongue cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00534-012-0532-8

21 January 2018

Number of metastatic lymph nodes, but not lymph node ratio, is an independent prognostic factor after resection of pancreatic carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00534-012-0532-8

21 January 2018

Identifiers

10.1007/S00534-012-0532-8

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22766692

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/22766692

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53153505&oldid=1164753755"